复星医药(600196.SH)控股子公司与Clavis Bio签订合作及选择权协议

智通财经2025-12-18

智通财经APP讯，复星医药(600196.SH)发布公告，2025年12月18日，公司控股子公司复星医药产业与合作方Clavis Bio签订《合作及选择权协议》，根据约定，于约定合作期限内，由复星医药产业与ClavisBio 共同选定靶点(基于 Clavis Bio 提名)并推进针对获选靶点化合物(即合作项目)的临床前开发。Clavis Bio 就该等合作项目享有除中国境内、香港、澳门外的全球范围...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2592972970?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-18 18:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592972970","market":"sh","top_or_hot":-1,"title":"复星医药(600196.SH)控股子公司与Clavis Bio签订合作及选择权协议","media":"智通财经","content":"<div>\n<p>智通财经APP讯，复星医药(600196.SH)发布公告，2025年12月18日，公司控股子公司复星医药产业与合作方Clavis Bio签订《合作及选择权协议》，根据约定，于约定合作期限内，由复星医药产业与ClavisBio 共同选定靶点(基于 Clavis Bio 提名)并推进针对获选靶点化合物(即合作项目)的临床前开发。Clavis Bio 就该等合作项目享有除中国境内、香港、澳门外的全球范围...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1383221.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药(600196.SH)控股子公司与Clavis Bio签订合作及选择权协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药(600196.SH)控股子公司与Clavis Bio签订合作及选择权协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-18 18:29 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1383221.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，复星医药(600196.SH)发布公告，2025年12月18日，公司控股子公司复星医药产业与合作方Clavis Bio签订《合作及选择权协议》，根据约定，于约定合作期限内，由复星医药产业与ClavisBio 共同选定靶点(基于 Clavis Bio 提名)并推进针对获选靶点化合物(即合作项目)的临床前开发。Clavis Bio 就该等合作项目享有除中国境内、香港、澳门外的全球范围...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1383221.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0183","symbol_name":"MSCI概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1383221.html","article_id":"2592972970","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592972970","pubTimestamp":1766053787,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，复星医药 发布公告，2025年12月18日，公司控股子公司复星医药产业与合作方Clavis Bio签订《合作及选择权协议》，根据约定，于约定合作期限内，由复星医药产业与ClavisBio 共同选定靶点并推进针对获选靶点化合物的临床前开发。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK0183":"MSCI概念","02196":"复星医药","BK0188":"融资融券","BK1191":"制药","BK1515":"抗疫概念","BK0096":"民营医院","BK0012":"证金概念","BK1593":"医美概念股","BK0196":"行业龙头","BK0175":"白马股","BK0187":"一线龙头","BK0060":"抗癌","BK0028":"国家队","BK0239":"医药制造"},"translate_title":"Fosun Pharma (600196. SH) holding subsidiary signed a cooperation and option agreement with Clavis Bio","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1.5,"02196":1.5},"content_text":"智通财经APP讯，复星医药(600196.SH)发布公告，2025年12月18日，公司控股子公司复星医药产业与合作方Clavis Bio签订《合作及选择权协议》，根据约定，于约定合作期限内，由复星医药产业与ClavisBio 共同选定靶点(基于 Clavis Bio 提名)并推进针对获选靶点化合物(即合作项目)的临床前开发。Clavis Bio 就该等合作项目享有除中国境内、香港、澳门外的全球范围内开发、生产及商业化独家许可的选择权;无论合作方是否行使上述选择权，集团就该等合作项目均享有于中国境内、香港、澳门独家开发、生产及商业化的权利。如本次合作中的某一合作项目获 Clavis Bio 行使选择权，就该单一合作项目而言，集团将可获得至多 36,250 万美元付款(包括不可退还的行权费、开发注册里程碑付款及销售里程碑付款)，并可基于该合作项目所涉产品于许可区域内的净销售额达成情况收取约定百分比例的特许权使用费;此外，集团还将以零对价对应获得 Clavis Bio 之控股股东(即 Aditum Bio Fund 3)为该合作项目而相应单独设立之新项目公司约定比例的少数股权。本次合作旨在充分发挥合作双方各自研发优势，进一步丰富集团高价值产品管线储备，且后期可通过潜在对外许可加快该(等)管线在全球范围的临床开发和商业化进程，持续拓展集团创新产品的海外布局。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592972970","isCrawlerRequest":true}